Tumor heterogeneity: morphological, molecular and clinical implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Malignant tumors exhibit significant heterogeneity and variability.
• Numerous oncogenic alterations contribute to diverse cancer types.
• Tumor heterogeneity impacts morphology, molecular profiles, and clinical outcomes.

Purpose of the Study:

• To review key aspects of carcinogenesis and chemoradiosensitivity in malignant cells.
• To highlight the role of oncogenes in anticancer agent resistance.
• To explore the correlation between molecular alterations, tumor characteristics, and treatment response.

Main Methods:

• Literature review summarizing carcinogenesis and chemoradiosensitivity.
• Discussion of specific oncogenes (neu, ras, bcl-2) and their association with treatment resistance.
• Exploration of novel gene therapy protocols based on molecular tumor profiling.

Main Results:

• Specific molecular alterations are not common across most human tumors, excluding certain hematologic and infant cancers.
• Oncogenes like neu, ras, and bcl-2 are linked to cellular resistance to anticancer drugs.
• Targeted gene therapies show promise for specific tumor types based on their molecular background.

Conclusions:

• Knowledge of oncogenic alterations is crucial for correlating tumor features, prognosis, and treatment response.
• Emerging gene therapy strategies offer personalized treatment approaches for cancer.
• Understanding tumor molecular profiles is key to advancing cancer treatment and patient outcomes.